Senzer Pharmaceuticals said yesterday that it has received the CE Mark for its cannabinoid inhaler.
London-based Senzer said the Class IIa medical device approval, obtained in a joint project with manufacturing partner Europlaz, is the first-ever granted in the cannabinoid space and will allow the company to accelerate its plans to launch in the UK and other European countries this year.
Get the full story on our sister site, Drug Delivery Business News.